United virus: The oncolytic tag-team against cancer!

Cytokine and Growth Factor Reviews

Volumn 21, Issue 2-3, 2010, Pages 205-211

  Le Bœuf, Fabrice ^a   Bell, John C ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Cancer; Oncolytic viruse; Vaccinia virus; Vesicular stomatitis virus; Virus combination

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VESICULAR STOMATITIS VIRUS; ONCOLYTIC VIRUS; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; GENETIC PREDISPOSITION; HUMAN; INTERFERON PRODUCTION; MATHEMATICAL MODEL; MELANOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; REVIEW; TUMOR; VESICULAR STOMATITIS; VIRUS RECOMBINATION; VIRUS REPLICATION; VIRUS VIRULENCE; ANIMAL; GENETICS; NEOPLASMS; PATHOLOGY; PHYSIOLOGY; PROCEDURES; VACCINIA VIRUS; VESICULOVIRUS; VIROLOGY;

ANIMALS; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VACCINIA VIRUS; VESICULOVIRUS;

VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 77953544495     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2010.02.008     Document Type: Review

References (40)

1. Parato K.A., Senger D., Forsyth P.A., Bell J.C. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005, 5(December (12)):965-976.
2. Bell J.C. Oncolytic viruses: what's next?. Curr Cancer Drug Targets 2007, 7(March (2)):127-131.
3. Russell S.J., Peng K.W. Viruses as anticancer drugs. Trends Pharmacol Sci 2007, 28(July (7)):326-333.
4. Aghi M., Martuza R.L. Oncolytic viral therapies-the clinical experience. Oncogene 2005, 24(November (52)):7802-7816.
5. Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?. Gene Ther 2001, 8(January (2)):89-98.
6. Park B.H., Hwang T., Liu T.C., Sze D.Y., Kim J.S., Kwon H.C., et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008, 9(June (6)):533-542.
7. Liu T.C., Hwang T., Park B.H., Bell J., Kirn D.H. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 2008, 16(September (9)):1637-1642.
8. Nguyen T.L., Abdelbary H., Arguello M., Breitbach C., Leveille S., Diallo J.S., et al. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci USA 2008, 105(September (39)):14981-14986.
9. Katsura T., Iwai S., Ota Y., Shimizu H., Ikuta K., Yura Y. The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells. Cancer Gene Ther 2009, 16(March (3)):237-245.
10. Otsuki A., Patel A., Kasai K., Suzuki M., Kurozumi K., Chiocca E.A., et al. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol Ther 2008, 16(September (9)):1546-1555.
11. McFadden G., Mohamed M.R., Rahman M.M., Bartee E. Cytokine determinants of viral tropism. Nat Rev Immunol 2009, 9(September (9)):645-655.
12. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005, 5(May (5)):375-386.
13. Stojdl D.F., Lichty B.D., tenOever B.R., Paterson J.M., Power A.T., Knowles S., et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003, 4(October (4)):263-275.
14. Breitbach C.J., Paterson J.M., Lemay C.G., Falls T.J., McGuire A., Parato K.A., et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 2007, 15(September (9)):1686-1693.
15. Stojdl D.F., Lichty B., Knowles S., Marius R., Atkins H., Sonenberg N., et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000, 6(July (7)):821-825.
16. Thorne S.H., Hwang T.H., O'Gorman W.E., Bartlett D.L., Sei S., Kanji F., et al. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest 2007, 117(November (11)):3350-3358.
17. Hummel J.L., Safroneeva E., Mossman K.L. The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma. Mol Ther 2005, 12(December (6)):1101-1110.
18. Hiraoka K., Kimura T., Logg C.R., Tai C.K., Haga K., Lawson G.W., et al. Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model. Cancer Res 2007, 67(June (11)):5345-5353.
19. Brown C.W., Stephenson K.B., Hanson S., Kucharczyk M., Duncan R., Bell J.C., et al. The p14 FAST protein of reptilian reovirus increases vesicular stomatitis virus neuropathogenesis. J Virol Jan 2009, 83(2):552-561.
20. Lichty B.D., Stojdl D.F., Taylor R.A., Miller L., Frenkel I., Atkins H., et al. Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. Hum Gene Ther 2004, 15(September (9)):821-831.
21. Lichty B.D., Power A.T., Stojdl D.F., Bell J.C. Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med 2004, 10(May (5)):210-216.
22. Wu Y., Lun X., Zhou H., Wang L., Sun B., Bell J.C., et al. Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors. Clin Cancer Res. 15 2008, 14(February (4)):1218-1227.
23. Boudreau J.E., Bridle B.W., Stephenson K.B., Jenkins K.M., Brunelliere J., Bramson J.L., et al. Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. Mol Ther 2009, 17(August (8)):1465-1472.
24. Moss B., Earl PL Overview of the vaccinia virus expression system. Curr Protoc Protein Sci 2001, (May). [Chapter 5:Unit 5.11].
25. Moss B. Poxvirus entry and membrane fusion. Virology 2006, 344(January (1)):48-54.
26. Thorne S.H. Oncolytic vaccinia virus: from bedside to benchtop and back. Curr Opin Mol Ther 2008, 10(August (8)):387-392.
27. Thorne S.H., Kirn D.H. Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus. Expert Opin Biol Ther 2004, 4(August (8)):1307-1321.
28. Naik S., Russell S.J. Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther 2009, 9(September (9)):1163-1176.
29. McCart J.A., Ward J.M., Lee J., Hu Y., Alexander H.R., Libutti S.K., et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001, 61(December (24)):8751-8757.
30. Mastrangelo M.J., Maguire H.C., Eisenlohr L.C., Laughlin C.E., Monken C.E., McCue P.A., et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 1999, 6(September-October (5)):409-422.
31. Prestwich R.J., Errington F., Diaz R.M., Pandha H.S., Harrington K.J., Melcher A.A., et al. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther 2009, 20(October (10)):1119-1132.
32. Alcami A., Smith G.L. Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J Virol 1995, 69(August (8)):4633-4639.
33. Alcami A., Symons J.A., Collins P.D., Williams T.J., Smith G.L. Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. J Immunol 1998, 160(January (2)):624-633.
34. Alcami A., Khanna A., Paul N.L., Smith G.L. Vaccinia virus strains Lister, USSR and Evans express soluble and cell-surface tumour necrosis factor receptors. J Gen Virol 1999, 80(April (Pt 4)):949-959.
35. Alcami A., Symons J.A., Smith G.L. The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J Virol 2000, 74(December (23)):11230-11239.
36. Kumagai T., Shimizu T., Ikeda S., Matumoto M. A new in vitro method (END) for detection and measurement of hog cholera virus and its antibody by means of effect of HC virus on Newcastle disease virus in swine tissue culture. I. Establishment of standard procedure. J Immunol 1961, 87(September):245-256.
37. Tsuchiya Y., Tagaya I. Enhanced or inhibited plaque formation of superinfecting viruses in Yaba virus-infected cells. J Gen Virol 1970, 7(April (1)):71-73.
38. Tsuchiya Y., Tagaya I. General characteristics of enhanced plague formation by poliovirus in poxvirus-infected cells. J Gen Virol 1972, 14(March (3)):229-235.
39. Tsuchiya Y., Tagaya I. Mechanism of enhanced plaque formation by poliovirus in poxvirus-infected cells. J Gen Virol 1972, 14(March (3)):237-242.
40. Faria P.A., Chakraborty P., Levay A., Barber G.N., Ezelle H.J., Enninga J., et al. VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway. Mol Cell 2005, 17(January (1)):93-102.